Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine:A Randomized, Double-Blind, Placebo-controlled Clinical Trial by Krivoy, Amir et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.ebiom.2017.11.027
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Krivoy, A., Onn, R., Vilner, Y., Hochman, E., Weizman, S., Paz, A., ... Weizman, A. (2017). Vitamin D
Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind,
Placebo-controlled Clinical Trial. EBioMedicine. DOI: 10.1016/j.ebiom.2017.11.027
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 15. Dec. 2017
Accepted Manuscript
Vitamin D Supplementation in Chronic Schizophrenia Patients
Treated with Clozapine: A Randomized, Double-Blind, Placebo-
controlled Clinical Trial
Amir Krivoy, Roy Onn, Yael Vilner, Eldar Hochman, Shira
Weizman, Amir Paz, Shmuel Hess, Roi Sagy, Shiri Kimhi-Nesher,
Ehud Kalter, Tal Friedman, Zvi Friedman, Gil Bormant, Sharon
Trommer, Avi Valevski, Abraham Weizman
PII: S2352-3964(17)30471-1
DOI: doi:10.1016/j.ebiom.2017.11.027
Reference: EBIOM 1273
To appear in: EBioMedicine
Received date: 30 June 2017
Revised date: 28 November 2017
Accepted date: 28 November 2017
Please cite this article as: Amir Krivoy, Roy Onn, Yael Vilner, Eldar Hochman, Shira
Weizman, Amir Paz, Shmuel Hess, Roi Sagy, Shiri Kimhi-Nesher, Ehud Kalter, Tal
Friedman, Zvi Friedman, Gil Bormant, Sharon Trommer, Avi Valevski, Abraham
Weizman , Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with
Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial. The address
for the corresponding author was captured as affiliation for all authors. Please check if
appropriate. Ebiom(2017), doi:10.1016/j.ebiom.2017.11.027
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the
journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
Vitamin D supplementation in chronic schizophrenia patients treated with clozapine: a 
randomized, double-blind, placebo-controlled clinical trial 
 
Amir Krivoy MDa,b,c,d,*, Roy Onn MDa,b,*, Yael Vilner BAa, Eldar Hochman MD PhDa,b,c, Shira 
Weizman MDa,b, Amir Paz MDa,b, Shmuel Hess MD MHAa,b, Roi Sagy MDb,e, Shiri Kimhi-
Nesher MD MSca,b, Ehud Kalter MDa,b, Tal Friedman MDa,b, Zvi Friedman RNa, Gil Bormant 
RN MAa, Sharon Trommer MDb, Avi Valevski MD MHAa,b, Abraham Weizman MDa,b,c 
aGeha Mental Health Center, Petah-Tikva, Israel 
bSacker Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel 
cLaboratory of Biological Psychiatry, Felsenstein Medical Research Center, Petah-Tikva, Israel 
dInstitute of Psychiatry, Psychology and Neuroscience, King’s college London, London, UK 
eBrill Mental Health Center, Tel-Aviv, Israel 
*Both authors contributed equally to this work 
Corresponding author: 
Amir Krivoy, MD 
Geha Mental Health Center 
1 Helsinki St., Petah Tikva, 49100002 
Tel: 972-3-2958220 
Fax: 972-3-9258746 
akrivoy@clalit.org.il  
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
Abstract 259/250 
Background 
While accumulating evidence suggests that vitamin D deficiency may be involved in the risk to 
develop schizophrenia and its outcome, there are no studies on vitamin D supplementation in this 
context. We sought to assess the effect of vitamin D supplementation on psychiatric, cognitive 
and metabolic parameters in chronic clozapine-treated schizophrenia patients. 
Methods 
This eight-week , randomized, double-blind, placebo-controlled clinical trial, recruited 
schizophrenia patients who had been maintained on clozapine treatment for at least 18 weeks and 
had low levels of vitamin D (<75 nmol/L) and total PANSS scores >70  (to  ascertain  the 
presence of residual symptoms). Patients were randomly allocated to either weekly oral drops of 
vitamin D (14,000 IU) or placebo and subsequently assessed at two-week intervals for psychosis 
severity, mood, cognition and metabolic profile. 
Results 
Twenty four patients were randomly assigned to vitamin D (aged 39.4 ± 9.6 years, 75% males) 
and the other 23 patients to the placebo arm (aged 42.5 ± 11.2 years, 60.9% males). After eight 
weeks, the vitamin D group exhibited a significant increase in vitamin D levels (31.4 vs -0.4 
nmol/L, p<0.0001).  There was no significant effect of vitamin D on psychotic, depressive or 
metabolic parameters. However, in the vitamin D group, there was a trend towards improved 
cognition (effect size=0.17, significance lost following Bonferroni correction).  
Conclusions 
Vitamin D supplementation was associated with a trend towards improved cognition, but did not 
affect psychosis, mood or metabolic status. It is possible that the robust decrease in the PANSS 
scores in both groups may have obscured an effect of vitamin D supplementation.  
Keywords: Clozapine; Vitamin D; Schizophrenia; Cognition; Mood; Metabolic syndrome 
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Highlights 
 This is the first study to explore the psychiatric, metabolic and cognitive effects of 
vitamin D supplementation in chronic schizophrenia patients maintained on clozapine 
 In this randomized, double-blind, placebo-controlled study 23 patients received vitamin 
D (14,000 IU weekly) and 24 received placebo for eight weeks 
 There was no significant difference between vitamin D and placebo with regards to the 
severity of psychopathology or metabolic status 
 There was a trend towards improved cognition following the effect of vitamin D, 
specifically in attention and delayed recall (memory) 
Research in context: 
About third of schizophrenia patients do not respond to common antipsychotics and require a 
clozapine trial. Insufficient levels of serum Vitamin D, the sunshine hormone, were found to be 
very prevalent among schizophrenia patients. The vitamin has a potent active metabolite with 
specific receptors in the brain. We investigated the psychiatric, metabolic and cognitive effects 
of vitamin D supplementation in comparison to placebo in clozapine-treated chronic 
schizophrenia patients with residual psychotic symptoms. Vitamin D addition was not superior to 
placebo in reducing psychiatric symptoms or improving the metabolic parameters. However, 
vitamin D administration was associated with a trend towards improvement in cognitive 
performance.  
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Introduction 
Chronic schizophrenia patients maintained on clozapine represent the most difficult-to-treat 
portion of this population (Kane 1996;Meltzer 1997). Clozapine treatment is indicated for 
patients who do not respond sufficiently to numerous other antipsychotic treatments (Suzuki et 
al. 2011). Still, unfortunately, about 50% of patients receiving clozapine remain with significant 
residual symptoms despite attempts at optimization of treatment and augmentation with other 
psychotropic drugs (Buckley et al. 2001). Moreover, there is no consensus on effective 
augmentation of clozapine treatment (Lieberman and Stroup 2011;Porcelli et al. 2011). Besides 
reducing psychotic burden, ameliorating cognitive impairments and negative symptoms is an 
important challenge for this population of schizophrenia patients. Impairment of executive 
functions and social cognition is one of the major disabilities in schizophrenia (Green and 
Harvey 2014;McCleery et al. 2014) .  
The prevalence of physical health comorbidities is high in schizophrenia patients (Correll et al. 
2017;De Hert et al. 2011;Vancampfort et al. 2016) and consists mainly of metabolic 
syndrome(De Hert et al. 2009c;Gardner-Sood et al. 2015;Vancampfort et al. 2015) that leads to a 
higher rate of cardiovascular morbidity(Correll, Solmi, Veronese, Bortolato, Rosson, 
Santonastaso, Thapa-Chhetri, Fornaro, Gallicchio, Collantoni, Pigato, Favaro, Monaco, Kohler, 
Vancampfort, Ward, Gaughran, Carvalho, & Stubbs 2017;De Hert et al. 2009a;Vancampfort et 
al. 2013). Cardio-metabolic complications are associated with significantly higher mortality rates 
and reduced life expectancy in the range of 15-20 years, compared to non-schizophrenia 
populations (De Hert et al. 2009b;Hjorthoj et al. 2017;Nielsen et al. 2013). Recently it was 
shown that low vitamin D levels are associated with increased risk for metabolic syndrome and 
cardiovascular illness in schizophrenia patients (Lally et al. 2016).  
The body content of 25 (OH) vitamin D is dependent on its synthesis in the skin by the enzyme 
25-hydroxylase and its consumption in the diet. Increasing evidence suggests that vitamin D is 
important to brain development (Cui et al. 2013;Eyles et al. 2003;Groves et al. 2013). The 
vitamin D receptor and the enzyme 1-α-hydroxylase that is needed for the hydroxylation of the 
precursor molecule 25(OH) vitamin D to the active form, have widespread expression in the 
adult human brain (Eyles et al. 2013). Animal models of rats deprived of vitamin D in-utero 
showed enhanced spontaneous hyperlocomotion and increased activity on the elevated plus maze 
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as well as impaired latent inhibition, which is a prominent feature of schizophrenia and 
attributable to impaired sensory gating and attentional deficits (Burne et al. 2014;Eyles et al. 
2009). Epidemiological studies found ecological factors associated with increased risk for 
developing schizophrenia, such as latitude, urbanicity and dark skin tone, factors that are 
associated also with hypovitaminosis D (McGrath et al. 2010a). Previous studies also showed 
that low blood vitamin D levels during the first year of life increase the risk for psychosis in 
males (McGrath et al. 2010b). Additionally, infants who did not receive sufficient vitamin D 
supplements were also found to be at risk to develop psychosis later in adulthood (McGrath et al. 
2004). Furthermore, several cross-sectional studies found high prevalence of vitamin D 
deficiency in schizophrenia patients (Boerman et al. 2016;Itzhaky et al. 2012) and two meta-
analyses concluded that the vitamin D levels of schizophrenia patients tend to be low, compared 
to healthy controls (Belvederi et al. 2013;Valipour et al. 2014). Vitamin D deficiency has also 
been suggested to be associated with cognitive impairment in people with psychotic disorders 
(Nerhus et al. 2017). 
However, the authors were unable to find any study that evaluated the direct effect of vitamin D 
supplementation on psychiatric, cognitive and metabolic status in schizophrenia patients and 
particularly in clozapine-treated patients.  This is specifically important for this population since 
there are limited further treatment options for clozapine-treated patients with residual symptoms. 
We hypothesized that Vitamin D supplementation may serve as a relatively safe adjunctive 
treatment for schizophrenia patients with a partial response to clozapine. We assumed that 
increasing vitamin D levels in clozapine-treated chronic schizophrenia patients may lead to a 
corresponding improvement in their psychotic, cognitive, affective and metabolic parameters. 
Materials and Methods 
Participants 
All inpatients and outpatients treated with clozapine during the period between 1.5.2014 and 
30.9.2016 at Geha Mental Health Center (GMHC) were identified using the electronic medical 
record registry (N=174). Potential participants were approached by the study nurse regarding 
participation in the study. The study was conducted according to the Consolidated Standards of 
Reporting Trials (CONSORT) guidelines (see CONSORT diagram – Figure 1).  
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Patients who consented to participate were assessed for eligibility criteria which included: age 
between 18 to 65 years old, diagnosis of schizophrenia according to DSM-IV-TR criteria 
confirmed by two senior psychiatrists, treated with clozapine for at least 18 weeks and being on a 
stable clozapine dose for at least four weeks prior to enrollment, serum 25(OH) vitamin D level 
below 75 nmol/L (30 ng/ml) and total severity of psychopathology score, as measured by the 
Positive and Negative Symptom Scale (PANSS) total score above 70. This threshold was chosen 
to ascertain that the patients had sufficient residual symptoms to be optimized by vitamin D 
addition and to avoid a floor effect. Exclusion criteria included: learning disability, organic brain 
disease, parathyroid disorder, inborn/acquired vitamin D metabolism disorders and patients 
already treated with vitamin D supplementation. The sample size was calculated as 45, based on 
an effect size of 0.6 (α = 0.05, power = 0.80) of the primary outcome measure (reduction in total 
PANSS score).  
The study was approved by GMHC's institutional review board and is registered on 
ClinicalTrials.gov (NCT01759485). All participants provided a written informed consent after 
receiving an explanation on the nature of the study prior to partaking in it. 
Investigational Medicinal Product and Masking 
Both vitamin D and placebo were provided, in sealed, identical, opaque bottles, by Solgar inc. 
(Petah-Tikva, Israel). The investigational medicinal products (IMP) were dispensed under the 
supervision of the study pharmacist. Upon recruitment, each patient was randomly assigned to 
either the vitamin D or the placebo group by a pre-prepared randomization code that was 
generated by the study pharmacist who was the only team member with an access to the 
information linking participants’ details to their study codes. Randomization was based on 1:1 
ratio between drug and placebo, and participants were sequentially assigned to the next treatment 
code of randomization. The IMP was administered on a weekly basis as oral drops (35 drops, 
14,000 IU per week, 0.35 mg) by the study nurse in order to ensure adherence to medication. As 
there are no agreed guidelines as to which dose is relevant to the effects of vitamin D on the 
brain, the IMP dose was chosen according to previously reported guidelines to achieve sufficient 
increase in serum levels (Van Groningen et al. 2010). A weekly-based administration was chosen 
to ascertain adherence to the study protocol. 
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Protocol and Design 
The study was a parallel arm design, randomized, double-blind, placebo-controlled, prospective 
clinical trial. 
Full assessments were carried out at baseline and after 8 weeks and included severity of the 
psychopathology, depression, cognition, metabolic parameters and safety measurements. 
Additionally, partial assessments that examined only severity of psychopathology and adverse 
events were done on a bi-weekly basis (visit 2 weeks, 4 weeks and 6 weeks). 
Outcome Measures 
The main outcome measure was the reduction in total Positive and Negative Symptoms Scale 
(PANSS) score. PANSS score ranges between 30 and 210 and patients were included in the 
study only if their baseline PANSS was above 70. 
Secondary variables included: measures of severity of sub-scales of psychopathology - PANSS-
positive (range 6 – 42), PANSS-negative (range 8 – 56) and PANSS-general psychopathology 
(range 16 – 102) sub-scores. Depressed mood was measured by the Calgary Depression Scale 
(CDS) which ranges between 0 and 27. Cognition was assessed using the Montreal Cognitive 
Assessment (MoCA) - a screening tool that has been proven to be sensitive in detecting minimal 
cognitive impairment in schizophrenia (Fisekovic et al. 2012). The instrument includes more 
items than the Mini-Mental Status Examination (MMSE) and also assesses executive functions 
relevant to schizophrenia such as abstraction and Clock Drawing Test.  The questionnaire 
includes 10 items (2 visuospatial, 1 naming, 3 attention, 2 language, 1 delayed memory recall 
and 1 orientation) whose score ranges between 0 and 30. Metabolic assessment included body-
mass index (BMI), waist circumference, blood pressure, pulse and blood tests for glucose, lipids 
and HbA1c.  
Serum 25(OH) vitamin D levels were analyzed at the Biochemistry Laboratory, Rabin Medical 
Center, Belinson Campus,  Petah Tikva, Israel using the ARCHITECT i2000SR immunoassay 
analyzer (Abbott,  Abbott Park, Illinois, USA). 
Safety 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
In each assessment, adverse events were screened using open questions and structured 
instruments such as the Sympson-Angus Scale (SAS) for extra-pyramidal side effects, Barnes 
Akathisia Rating Scale (BARS) and Clozapine Adverse Events Inventory (CAEI). The CAEI 
was developed on the basis of the Glasgow Antipsychotic Side‐effect Scale (GASS) (Waddell 
and Taylor 2008)  specifically for this study to monitor the existence and severity of 19 common 
clozapine side effects. Other measures of safety included an electrocardiogram to monitor QTc 
interval and routine clinical blood tests at baseline and at the eight week point. 
Statistical analysis 
Data were analyzed using SPSS version 20 software (IBM Corporation, Armonk, New York). 
Univariate differences between groups were assessed using Student’s t-test, Mann-Whitney test 
or χ2 as appropriate. All patients who were randomly assigned to one of the two groups were 
included in the final analysis, as the study was designed as intention-to-treat with last 
observation carried forward in case of missing data. The superior effect of the drug over placebo 
on repeated measures over time was analyzed using General Linear Model with repeated 
measurements, taking into consideration time, effect of the drug and their interaction. Secondary 
outcome measures that were found to be significantly affected by vitamin D between the two 
time points (baseline and endpoint) were examined by post-hoc exploratory analysis, adjusting 
for age, sex, length of illness and season of study entry. Bonferroni post-hoc test for multiple 
comparisons was used as appropriate and significance levels were set accordingly (p<0.004). We 
further performed a sub-analysis comparing supplementation with no supplementation in those 
with low baseline vitamin D levels (<50 nmol/L). In addition we assessed the possible 
correlation between change in vitamin D levels and change in the outcome measures for those 
with low baseline vitamin D. 
Results 
Out of the 174 screened patients, 47 (mean age 40.9±1.5 years, range 22 -65, 32 [68%] males, 
mean daily clozapine dose 414.4±20, range 200 - 700 mg, mean duration of illness 16.2±1.5 
years) were randomly assigned to either the vitamin D group or the placebo group. See Figure 1 
for the specific reasons for the exclusion of 127 patients screened. Twenty four patients from the 
vitamin D group and 23 from the placebo group were analyzed using Intent-To-Treat design. The 
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two groups’ baseline characteristics are depicted in Table 1. There was no statistical difference in 
any of the baseline measures between the drug and placebo groups. 
Vitamin D levels 
The mean serum 25(OH) vitamin D level of the whole sample (N=47) at baseline was 39.8±16.2 
nmol/L (median 39.2, range 0 – 69.3). Baseline serum 25(OH) vitamin D levels of the two 
groups appear on Table 1. At baseline, 33 (70%) patients had insufficient vitamin D blood levels 
(i.e. < 50 nmol/L). Of those, 10 patients (21%) were deficient (<25 nmol/L) with 3 (13%) 
patients in the placebo group and 7 (29%) in the drug group. The 25(OH) vitamin D serum levels 
increased significantly in the drug group (from 37.2 to 68.6, t(23)=-6.3, p<0.0001) while 
essentially unchanged in the placebo group (from 42.7 to 42.3 nmol/L , t(22)=0.114, p=0.91 ). At 
endpoint, there were 4 (17%) patients with deficient levels of 25(OH) vitamin D in the placebo 
group and only one patient (4%) in the vitamin D group. This patient, despite attending all 
assessments and dosing visits, showed vitamin D level of 22 nmol/L at baseline and 17 nmol/L at 
endpoint due to unclear reasons. 
Clinical measures 
No between group differences were found in the repeated measures model of PANSS total or in 
the sub-scores measures (Figure 2). Using general linear model with repeated measures, the only 
significant effect found was that of time, for both groups, but none of vitamin D X time 
interaction. PANSS total: F(45)=14.85, p<0.0001 for time, F(45)=0.17, p=0.95 for interaction, 
PANSS positive: F(45)=12.93, p<0.0001 for time, F(45)=0.67, p=0.61 for interaction, PANSS 
negative: F(45)=9, p<0.0001 for time, F(45)=0.5, p=0.74 for interaction and PANSS general 
psychopathology: F(45)=10.5 p<0.0001 for time, F(45)=0.25, p=0.91 for interaction. 
Furthermore, no significant association was found between the change in vitamin D serum levels 
from baseline to endpoint and PANSS total and sub-scores changes. 
Comparison of the change in scores of the various outcome measures between baseline and 
endpoint (eight weeks) is presented in Table 2. There was a significant difference in the change 
of the MoCA total score between the vitamin D and placebo groups (0.9 vs -0.6, p=0.04, 
respectively), however this effect is lost following Bonferroni correction for multiple 
comparisons. When tested using the general linear model with repeated measures, time was 
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found to be insignificant [F (44) =0.21, p=0.65], however, vitamin D X time interaction was 
significant [F (44) =4.46, p=0.04.]; though significance is lost following Bonferroni correction, 
since the adequate significance value was set to p<0.004 (Table 2). Noteworthy, a multivariate 
regression analysis, adjusting for age, sex, length of illness and season at the study entry showed 
that vitamin D supplementation was associated with larger increase of MoCA score (B=1.77, 
β=0.18, SE=0.7, t=2.52, p=0.016) from baseline. 
Exploratory, post-hoc analysis was further performed to see the relative contribution of the 
MoCA components to the change in the composite score. Delayed recall (memory) and attention 
were found to have changed significantly in the vitamin D group but not in the placebo group, 
although significance was lost following Bonferroni correction for multiple comparisons of the 
MoCA components (the required p=0.007;Figure 3). Delayed recall item includes remembering 
five words during the interview. Point being given to every word remembered spontaneously 
without cue. Participants on vitamin D had an increased mean score on this item from 1.16 at 
baseline to 1.7 at endpoint (z=-1.9, p=0.049) while participants on placebo had mean score of 
1.55 at baseline and 1.45 at endpoint (z=-0.36, p=0.72). Attention score is a summation of three 
items: forwards and backward digit span scored one point each, vigilance for sequence of letters 
scored one point and serial sevens scored up to three points. Participants on vitamin D increased 
significantly mean attention score from 4.17 at baseline to 4.58 at endpoint (z=-2.23, p=0.026), 
while the increase in mean attention score in the participants on placebo (from 3.95 at baseline to 
4.04 at endpoint) did not reach statistical significance (z=-0.35, p=0.725).   
Metabolic measures 
There was no difference between the vitamin D and placebo groups with regard to change in 
metabolic parameters over time (see Table 2). Neither was there an effect of time on these 
parameters. There was also no linear association between the change in vitamin D serum levels 
and change in any of the metabolic parameters explored.  
Adverse events 
Baseline rates of side effects were similar between groups. There were no severe adverse events 
noted during follow-up in both groups. As shown in Table 3, vitamin D group exhibited slightly 
more gastro-intestinal complaints: two patients reported nausea, three reported diarrhea and one 
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reported abdominal discomfort. There was no significant difference between groups in the level 
of total CAEI score reduction (taking into account also the severity of adverse event): Vitamin D 
group 1.58 vs 1.77 placebo group, t=0.18, p= 0.86).  
Sub-analysis according to the change in vitamin D levels 
One of the assumptions of the study was that the beneficial effects of Vitamin D will be more 
pronounced in those with low baseline vitamin D levels, who achieved normalization of vitamin 
blood levels following the supplementation. Therefore, we further performed sub-analyses for a 
subset of patients with pronounced low baseline vitamin D (<50 nmol/L, N=33). We compared 
the psychiatric, cognitive and metabolic parameters between patients who were supplemented 
with vitamin D (n=17) to those who were on placebo (n=16). Sub-groups’ characteristics appear 
on Supplementary Tables 1 and 2. There were no statistically significant differences between the 
sub-groups in changes of psychosis, mood and metabolic parameters, as well as MoCA scores, 
between baseline and endpoint. A significant increase in HDL levels was detected in patients 
who received vitamin D, but the significance is lost following Bonferroni correction for multiple 
comparisons (Supplementary Table 1; the required p is 0.003). Finally, we did not detect any 
significant correlation between changes in vitamin D levels and changes in outcome measures. 
 
Discussion 
This is the first study to explore the effect of vitamin D supplementation on schizophrenia 
patients in general and more specifically when used as an add-on to clozapine. After eight weeks 
of follow-up the main finding was that the effect of vitamin D on psychiatric symptoms and 
metabolic parameters did not differ significantly from that of placebo. It is possible that the 
robust decrease in the PANSS scores in both groups may have obscured an effect of vitamin D 
supplementation .A beneficial effect of vitamin D supplementation was noted on cognitive 
performance, as reflected in an increase in MoCA total score. However, this impact was with a 
small effect size (Cohen’s d= 0.17) and was attributable to improvements in attention and 
memory domains only. Moreover, the significance of the improvements in the total MoCA and 
the two components was lost following Bonferroni correction for multiple comparisons. 
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The study sample demonstrated relatively high rate of low vitamin D levels. Of 62 patients 
assessed for eligibility to participate in the current study, 52 (83.8%) were found to have 
insufficient levels of vitamin D (<75 nmol/L). This high rate is within the range reported in a 
recent meta-analysis, that found an overall prevalence of vitamin D deficiency of 65.3% (95% CI 
46.4%-84.2%) in schizophrenia patients (Valipour, Saneei, & Esmaillzadeh 2014). Another 
study reported 86% in a cohort of patients with established psychosis (Lally, Gardner-Sood, 
Firdosi, Iyegbe, Stubbs, Greenwood, Murray, Smith, Howes, & Gaughran 2016) ,while another 
(Boerman, Cohen, Schulte, & Nugter 2016) from the Netherlands, showed a rate of 34.9% 
deficient and 65.8% insufficient vitamin D levels among schizophrenia outpatients. Although 
Israel is sunny most of the year, the rate of vitamin D deficiency among schizophrenia patients 
was previously shown to be 57.1% (< 40 nmol/L) (Itzhaky, Amital, Gorden, Bogomolni, Arnson, 
& Amital 2012) and 98% insufficiency (< 75 nmol/L). 
Current evidence for vitamin D involvement in schizophrenia derives mainly from ecological 
data and association studies.  A Finnish birth cohort study showed that vitamin D 
supplementation of at least 2000 IU per day to male infants during the first year of life reduced 
the risk of developing schizophrenia by 77% compared with those receiving lower daily doses 
(McGrath, Saari, Hakko, Jokelainen, Jones, Jarvelin, Chant, & Isohanni 2004). Similarly, studies 
showed that low maternal vitamin D status may increase the subsequent risk of schizophrenia in 
the developing fetus (McGrath, Burne, Feron, Mackay-Sim, & Eyles 2010a). The authors were 
unable to find studies on the efficacy of vitamin D supplementation on psychosis. Notably, a 
recent study (Saad et al. 2016) showed a positive effect of vitamin D supplementation in young 
patients with autism, especially regarding behavioral measures. The current study did not 
demonstrate a differential effect of vitamin D in comparison to placebo regarding the impact on 
the severity of psychopathology in clozapine-treated patients. This lack of a beneficial effect in 
the current study may be attributed to the fact that the participants included treatment-resistant 
population that had been treated with several antipsychotic compounds for years (mean length of 
illness 16 years) and may thus be amenable to minor changes only. Positive effects of vitamin D 
may be more pronounced in early phases of schizophrenia, when the brain pathology is at its 
early stage. 
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In this study vitamin D was found mildly superior to placebo (effect size=0.17) in improving 
cognition as measured by the total score of the screening tool MoCA, mainly with regard to 
attention and delayed recall domains. This finding should be considered with caution, as 
correction made for repeated measures led to loss of significance of the two cognitive 
components that were improved, and there is a risk of Type I error. However, taking into 
consideration the relatively small sample size, the short period of the trial and putatively the low 
dosage of vitamin D, this preliminary result may suggest that prolongation of the duration of 
exposure to vitamin D supplementation of a larger dose of vitamin D and a larger sample size 
might have shown a more robust effect.  Consistent with our observation, epidemiological 
studies showed a positive association between vitamin D levels and cognitive performance, 
especially in older adults (Przybelski and Binkley 2007;Wilkins et al. 2006). Recent data from a 
case-control study demonstrated that vitamin D levels correlated with negative and cognitive 
symptoms in first episode psychosis patients as opposed to a control group (Graham et al. 2015). 
Another cross-sectional study (Nerhus, Berg, Simonsen, Haram, Haatveit, Dahl, Gurholt, Bjella, 
Ueland, Andreassen, & Melle 2017) showed that vitamin D deficiency in schizophrenia patients 
was significantly associated with decreased processing speed and decreased verbal fluency; 
however negative symptoms diluted that association. Moreover, in vitamin D deficient multiple 
sclerosis patients, three months of vitamin D supplementation was associated with a significant 
improvement in total MoCA and delayed recall scores (Darwish et al. 2017). However, a study in 
healthy subjects showed no superiority of vitamin D supplementation (5000 IU daily for six 
weeks) over placebo in improving cognitive performance (Dean et al. 2011). This may suggest 
that a beneficial effect of vitamin D on cognition is more apparent in cognitively impaired 
patients (such as subjects with schizophrenia) than in the normal functioning brain. As these 
results should be interpreted cautiously, future studies may be able to detect the effect more 
robust by using a more comprehensive cognitive assessment battery.   
Heart failure, hypertension, stroke, and other cardiovascular diseases (CVD) in the general 
population have been associated with lower vitamin D levels (Liu et al. 2012) and there is an 
inverse relationship between serum vitamin D levels and hypertension, obesity and waist 
circumference (Lindqvist 2014). A recent study, investigating a cohort of 324 chronic patients 
with psychosis (Lally, Gardner-Sood, Firdosi, Iyegbe, Stubbs, Greenwood, Murray, Smith, 
Howes, & Gaughran 2016) showed that 25(OH) vitamin D levels were negatively correlated with 
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waist circumference, BMI, total cholesterol, triglycerides, HbA1c and hypertension. The current 
study however did not find any beneficial effect of vitamin D supplementation (and subsequent 
corresponding increase in serum 25(OH) vitamin D levels) on metabolic parameters. This may 
imply that the metabolic parameters are resistant to change in this unique population of chronic 
clozapine-treated patients. The lack of effect may also be related to the relatively short period of 
the study (eight weeks). Future supplementation studies should use larger doses of vitamin D and 
continue for longer follow-up periods. 
Limitations 
This is an innovative study, exploring for the first time, the effects of vitamin D in a population 
of treatment resistant schizophrenia patients maintained on clozapine. The results however, 
should be interpreted with caution due to the study's limitations. The study included a relatively 
small sample size, however, one should keep in mind that this is a population of severely ill 
patients, making recruitment of participants quite challenging. Moreover, most clozapine 
augmentation studies in the available literature had similar small sample sizes. Since patients 
with extreme presentation are less likely to consent to participate in a randomized controlled trial 
due to their paranoid and suspicious attitudes, thus the study population may be slightly biased 
towards less severe cases. However, all patients had residual symptoms and they may indeed 
represent the substantial portion of chronic clozapine-treated patients who would eventually 
adhere to vitamin D supplementation.  
Another limitation is the fact that no adjustment was done for ethnicity, which is an important 
factor in vitamin D skin synthesis. But, since this study included a quantitative measure of serum 
vitamin D that reflects both its synthesis and absorption, hence, ethnicity, as well as other factors 
that may affect absorption, seem to be less relevant.  
Conclusions 
This is the first study to explore the effects of vitamin D supplementation on schizophrenia 
patients in general and in clozapine-treated schizophrenia patients in particular.  No significant 
advantage of vitamin D over placebo on psychotic, depressive and metabolic parameters was 
found. A mild positive effect was demonstrated on cognitive performance. Regression analysis, 
adjusting for age, sex, length of illness and season at the study entry showed that Vitamin D 
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supplementation was a significant predictor of higher total MoCA score (B=1.77, β=0.18, 
SE=0.7, t=2.52, p=0.016).Thus it appears that vitamin D supplementation may improve to some 
extent the cognitive performance in this population of clozapine-treated schizophrenia patients. 
However, further studies are needed to confirm such a pro-cognitive effect in earlier phases of 
the disorder, using a larger sample, a more sensitive cognitive assessment, longer duration and 
larger doses of vitamin D supplementation. 
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Table 1: Baseline characteristics of the participants by study group.   
PANSS: Positive and Negative Symptom Scale; MoCA: Montreal Cognitive Assessment; BMI: 
Body Mass Index; HDL: High Density Lipoprotein;  
 Vitamin D  
(N=24) 
Placebo  
(N=23) 
Statistics P 
Age – Mean 39.4 ± 9.6 42.5 ± 11.2 t(45)=1.02  0.31 
Age – Range 26 – 63 22 – 65   
Sex -Males (%) 18 (75) 14 (60.9) χ2(1)=1.08 0.36 
Immigrants (%) 8 (33.3) 5 (21.7) χ2(1)=0.37 0.29 
Singles (%) 19 (79.2) 16 (69.6) χ2(1)=0.45 0.34 
Smoking (%) 13 (54.2) 11 (47.8) χ2(1)=0.66 0.44 
Length of illness – 
(years) 
15.3 ± 11.1 17.2 ± 9.5 z(44)=-1.07 0.29 
Clozapine daily 
dose (mg) 
414.6 ± 131.6 414.1 ± 131.6 z(45)=-0.29 0.77 
Vitamin D (nmol/L) 37.2 ± 5.9 42.7 ± 15.5 t(45)=1.17 0.25 
PANSS Total 81.8 ± 9.2 87.4 ± 13.7 z(45)=-0.16 0.11 
PANSS Positive 17.8 ± 5.1 19.9 ± 6.3 z(45)=-1.12 0.2 
PANSS Negative 26.6 ± 5.9 26.7 ± 4.6 z(45)=-0.31 0.76 
PANSS General 37.1 ± 7.9 40.8 ± 8.1 z(45)=-1.4 0.16 
Calgary Depression 
Scale 
4.5 ± 4.2 5.2 ± 3.4 z(45)=-1.22 0.22 
MoCA total score 21.7 ± 5.5 21.7 ± 4.7 z(45)=-0.27 0.8 
BMI (Kg/m2) 28.3 ± 3.8 28.1 ± 6 t(45)=-0.12 0.9 
Waist 
Circumference (cm) 
104.5 ± 9 99.1 ± 25.5 t(45)=-0.44 0.66 
HDL (mg/dL) 49 ± 26.6 48.4 ± 22.4 z(45)=-0.6 0.95 
Triglycerides 
(mg/dL) 
176.8 ± 76.7 243.2 ± 229.5 z(45)=-0.68 0.5 
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Glucose (mg/dL) 111.8 ± 34 114.3 ± 60.3 z(45)=-0.45 0.65 
HbA1C (%) 5.7 ± 0.7 6.0 ± 1.8 z(45)=-0.48 0.63 
Systolic blood 
pressure (mmHg) 
124.4 ± 9.8 128.3 ± 15.5 t(45)=1.02 0.31 
Pulse (bpm) 99.5 ± 18.3 99.7 ± 9.8 t(45)=0.06 0.95 
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Table 2: Mean changes, between baseline and the eight week follow-up (two time points), in 
clinical and metabolic parameters of the vitamin D and placebo groups (endpoint-baseline 
scores) 
 Vitamin D 
(n=23) 
Placebo 
(n=24) 
Statistics P Effect size 
(Cohen’s 
D) 
PANSS Total  -8.9 (7.3) -10 (10.2) t(45)=0.45 0.65 -0.13 
PANSS Positive -3 (2.1) -3.5 (3.8) t(45)=0.53 0.59 -0.16 
PANSS Negative -3.7 (4.1) -2.7 (4) t(45)=-0.83 0.41 0.24 
PANSS General -2 (8.4) -3.9 (4.9) t(45)=1.49 0.14 -0.45 
Calgary Depression 
Scale 
-0.5 (2.7) -0.8 (1.8) t(44)=0.52 0.6 -0.16 
MoCA total score 0.9 (1.9) -0.6 (2.9) t(44)=2.1 0.04a 0.17 
BMI (Kg/m2) -0.4 (1.6) -0.1 (1.2) t(44)=0.58 0.56 0.18 
Waist Circumference 
(cm) 
-0.4 (4.1) -0.7 (7.9) t(44)=0.17 0.86 0.05 
HDL (mg/dL) -7 (27.3) -3.1 (17.3) t(39)=-0.55 0.58 0.18 
Triglycerides (mg/dL) 11.5 (44) -43.9 (130.8) t(39)=1.83 0.07 -0.63 
Glucose (mg/dL) 4.3 (32.1) -12.2 (44.7) t(44)=1.44 0.15 0.43 
HbA1C (%) -0.3 (0.4) -1.1 (2.5) t(15)=0.07 0.35 -0.55 
Systolic Blood pressure 
(mmHg) 
-1.6 (11.4) -1.1 (16) t(44)=-0.13 0.89 0.04 
Pulse (bpm) 1.3 (15.4) -3.5 (25.1) t(44)=0.78 0.43 -0.24 
 
a Significance is lost following Bonferroni correction for multiple comparisons (significant value 
defined as p=0.004)  
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Table 3: Adverse events reported by participants during the 8-week follow-up period. Numbers 
represents patients with reported item. 
SAS: Simpson-Angus Scale; BARS: Barnes Akathisia Rating Scale; CAEI: Clozapine Adverse 
Effects Inventory 
 Vitamin D 
(n=23) 
Placebo  
(n=24) 
Somnolence   
Slow thinking   
Restlessness  2 
Confusion   
Palpitations   
Tachycardia  2 
Shortness of 
breath 
1  
Constipation   
Nausea 2  
Diarrhea 3  
Abdominal 
discomfort 
1  
Salivation during 
day 
  
Salivation during 
night 
 1 
Increased appetite 1 1 
Weight gain   
Dizziness 2  
Tremor  1 
Urine incontinence 
during day 
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Urine incontinence  
during night 
 2 
Total CAEI  -1.58 -1.78 
SAS > 10 1 1 
BARS >0 1  
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Figure legends: 
Figure 1: CONSORT flow chart of the study recruitment and follow-up process 
Figure 2: Mean (±S.E) Positive and Negative Symptoms Scale (PANSS) total and sub-
scores in the repeated assessments during the eight weeks of the trial, in the vitamin D 
(n=24) and placebo groups (n=23). There was no statistically significant difference between 
the placebo and vitamin D groups in any of the presented variables.   
Figure 3: Mean (±S.E) scores of Montreal Cognitive Assessment (MoCA) domains in the 
vitamin D and placebo groups at baseline and endpoint (eight weeks). There was a 
significant increase in memory and attention scores in the vitamin D group only (*p<0.05; 
however significance of these two domains is lost following Bonferroni correction for 
multiple comparisons: the required p value is p=0.007). 
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Figure 1: 
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